Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA cholesterol acyltransferase (ACAT), also known as sterol O-acyltransferase (SOAT), is a membrane-bound enzyme that catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty acyl-CoA. This reaction is crucial for cellular cholesterol homeostasis, as it converts potentially toxic free cholesterol into a storage form—cholesteryl esters—which are sequestered in cytoplasmic lipid droplets or incorporated into lipoproteins. There are two main isoenzymes in mammals: ACAT1 (SOAT1), ubiquitously expressed and primarily involved in intracellular cholesterol homeostasis, and ACAT2 (SOAT2), mainly in the liver and intestine, playing a key role in lipoprotein assembly. ACAT activity is implicated in diseases like atherosclerosis, Alzheimer's, and cancer, making it a potential therapeutic target.
Inhibition of cholesterol esterification
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA Cholesterol Acyltransferase (ACAT).